Scotia Capital’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $776K | Sell |
9,686
-85
| -0.9% | -$7.01K | ﹤0.01% | 606 |
|
|
2025
Q4 | $833K | Sell |
9,771
-265
| -3% | -$21.7K | ﹤0.01% | 590 |
|
|
2025
Q3 | $781K | Sell |
10,036
-955
| -9% | -$74.6K | ﹤0.01% | 600 |
|
|
2025
Q2 | $860K | Sell |
10,991
-1,146
| -9% | -$85.5K | ﹤0.01% | 555 |
|
|
2025
Q1 | $880K | Sell |
12,137
-2,962
| -20% | -$212K | ﹤0.01% | 536 |
|
|
2024
Q4 | $1.12M | Buy |
+15,099
| New | +$1.06M | 0.01% | 504 |
|
|
2024
Q3 | – | Sell |
-19,099
| Closed | -$1.76M | – | 853 |
|
|
2024
Q2 | $1.76M | Sell |
19,099
-554
| -3% | -$49.1K | 0.01% | 396 |
|
|
2024
Q1 | $1.88M | Sell |
19,653
-2,733
| -12% | -$230K | 0.01% | 382 |
|
|
2023
Q4 | $1.71M | Buy |
22,386
+905
| +4% | +$63K | 0.01% | 375 |
|
|
2023
Q3 | $1.49M | Sell |
21,481
-707
| -3% | -$56.8K | 0.01% | 381 |
|
|
2023
Q2 | $2.09M | Sell |
22,188
-1,016
| -4% | -$88.3K | 0.01% | 336 |
|
|
2023
Q1 | $1.92M | Buy |
23,204
+3,415
| +17% | +$268K | 0.01% | 355 |
|
|
2022
Q4 | $1.48M | Buy |
19,789
+8,884
| +81% | +$685K | 0.01% | 394 |
|
|
2022
Q3 | $901K | Buy |
10,905
+154
| +1% | +$14.8K | 0.01% | 468 |
|
|
2022
Q2 | $1.02M | Sell |
10,751
-11,173
| -51% | -$1.16M | 0.01% | 471 |
|
|
2022
Q1 | $2.58M | Sell |
21,924
-756
| -3% | -$84.8K | 0.02% | 355 |
|
|
2021
Q4 | $2.94M | Buy |
22,680
+1,749
| +8% | +$204K | 0.02% | 344 |
|
|
2021
Q3 | $2.37M | Sell |
20,931
-42
| -0.2% | -$4.79K | 0.02% | 369 |
|
|
2021
Q2 | $2.17M | Buy |
20,973
+328
| +2% | +$30.9K | 0.02% | 376 |
|
|
2021
Q1 | $1.73M | Buy |
20,645
+1,287
| +7% | +$109K | 0.01% | 380 |
|
|
2020
Q4 | $1.77M | Buy |
19,358
+766
| +4% | +$63.5K | 0.02% | 350 |
|
|
2020
Q3 | $1.48M | Buy |
+18,592
| New | +$1.45M | 0.02% | 341 |
|
|
2020
Q2 | – | Sell |
-17,130
| Closed | -$1.08M | – | 676 |
|
|
2020
Q1 | $1.08M | Buy |
17,130
+2,166
| +14% | +$156K | 0.02% | 325 |
|
|
2019
Q4 | $1.16M | Buy |
14,964
+8,022
| +116% | +$626K | 0.01% | 375 |
|
|
2019
Q3 | $509K | Buy |
+6,942
| New | +$488K | 0.01% | 514 |
|
|
2018
Q1 | – | Sell |
-20,730
| Closed | -$779K | – | 720 |
|
|
2017
Q4 | $779K | Buy |
20,730
+465
| +2% | +$17.1K | 0.01% | 449 |
|
|
2017
Q3 | $738K | Sell |
20,265
-750
| -4% | -$28.6K | 0.01% | 458 |
|
|
2017
Q2 | $828K | Sell |
21,015
-780
| -4% | -$28.5K | 0.01% | 404 |
|
|
2017
Q1 | $684K | Sell |
21,795
-2,049
| -9% | -$64.2K | 0.01% | 458 |
|
|
2016
Q4 | $745K | Buy |
23,844
+11,964
| +101% | +$388K | 0.01% | 491 |
|
|
2016
Q3 | $476K | Sell |
11,880
-444
| -4% | -$16.7K | 0.01% | 571 |
|
|
2016
Q2 | $410K | Buy |
+12,324
| New | +$422K | 0.01% | 543 |
|
|
2014
Q2 | – | Sell |
-32,526
| Closed | -$402K | – | 583 |
|
|
2014
Q1 | $402K | Sell |
32,526
-2,100
| -6% | -$24.2K | 0.01% | 435 |
|
|
2013
Q4 | $379K | Buy |
34,626
+12,210
| +54% | +$138K | 0.01% | 414 |
|
|
2013
Q3 | $260K | Buy |
22,416
+1,980
| +10% | +$23.2K | 0.01% | 426 |
|
|
2013
Q2 | $229K | Buy |
+20,436
| New | +$242K | 0.01% | 411 |
|
Other funds holding EW
VCM
VPM
Scotia Capital's EW Position: Q1 2026 in Review
Scotia Capital reduced its Edwards Lifesciences (EW) stake by 0.87% in Q1 2026, selling an estimated $7.01K and leaving 9,686 shares worth $776K. The position accounts for ﹤0.01% of the portfolio, ranked #606.
Scotia Capital first reported a position in EW in Q2 2013 and has held it in 36 quarters since. The position peaked at $2.94M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Scotia Capital held 9,686 shares of Edwards Lifesciences worth $776K as of Q1 2026.
- Scotia Capital sold 85 Edwards Lifesciences shares in Q1 2026, an estimated $7.01K.
- Edwards Lifesciences made up ﹤0.01% of Scotia Capital's portfolio in Q1 2026, its #606 holding.
- Scotia Capital first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 36 quarters since.
- Scotia Capital's Edwards Lifesciences position peaked at $2.94M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.